Taniguchi Hiroaki, Imai Kohzoh
Clinical and Translational Research Center, Keio University, Tokyo, Japan.
The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Methods Mol Biol. 2019;1974:233-243. doi: 10.1007/978-1-4939-9220-1_18.
The PRDI-BF1 and RIZ (PR) domain zinc finger protein 14 (PRDM14) is upregulated in approximately 60% of breast cancers, some of which exhibit gene amplification. In contrast, PRDM14 is not expressed in normal, and differentiated tissues. PRDM14 breast cancer cells are resistant to chemotherapy drugs, are tumorigenic, and metastasize to the lungs. It is commonly assumed that genes that are overexpressed in cancers, such as PRDM14, are effective targets for new therapies that specifically abrogate the expression of these genes. RNA interference of PRDM14, a gene expressed by breast cancer cells, reduced the size of tumors and lung metastases in nude mice. In this chapter, we introduce the concept and methods to develop and apply systematically injected small interfering RNA therapy for breast cancer models in vivo.
PRDI-BF1和RIZ（PR）结构域锌指蛋白14（PRDM14）在约60%的乳腺癌中上调，其中一些存在基因扩增。相比之下，PRDM14在正常组织和分化组织中不表达。PRDM14阳性的乳腺癌细胞对化疗药物耐药，具有致瘤性，并可转移至肺部。通常认为，在癌症中过表达的基因，如PRDM14，是特异性消除这些基因表达的新疗法的有效靶点。对乳腺癌细胞表达的PRDM14进行RNA干扰，可减小裸鼠体内肿瘤的大小并减少肺转移。在本章中，我们介绍了在体内乳腺癌模型中开发和应用系统性注射小干扰RNA疗法的概念和方法。
